Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anthrax lethal factor inhibition.

W L Shoop1, Y Xiong, J Wiltsie

  • 1Merck Research Laboratories, Rahway, NJ 07065, USA. weseley_shoop@merck.com

Proceedings of the National Academy of Sciences of the United States of America
|May 25, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards a framework for prioritizing diagnostics in the global AMR response.

JAC-antimicrobial resistance·2026
Same author

Two-Peak Heat Capacity Accounts for Rln(2) Entropy and Ground State Access in the Dipole-Octupole Pyrochlore Ce_{2}Hf_{2}O_{7}.

Physical review letters·2025
Same author

Stellate ganglion block and ventricular arrhythmias.

QJM : monthly journal of the Association of Physicians·2024
Same author

Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

A comparative evaluation of fluoride release and rechargeability in conventional GIC (type II), pediatric GIC (type IX), and Cention-N: an in vitro study.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry·2024
Same author

Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same journal

Chemotactic self-organization captures the dynamics of mammalian hair follicle patterning.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Tomographic imaging of superconducting order using particle-hole interference.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inhibitory potential of autologous neutralizing antibodies sets quantitative limits on the rebound-competent HIV-1 reservoir.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inferring epidemiological parameters under an infectious phylogeography model with visitor dynamics.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Analytical modeling for suction cup designs for skin-interfaced wearable devices.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Improving cell-free metabolism through direct integration of artificial respiratory chains.

Proceedings of the National Academy of Sciences of the United States of America·2026
See all related articles
This summary is machine-generated.

A novel hydroxamate inhibitor effectively blocks Bacillus anthracis lethal factor (LF) protease activity. This small molecule demonstrated significant protection in animal models, offering a potential adjunct therapy for anthrax.

Area of Science:

  • Biochemistry
  • Microbiology
  • Pharmacology

Background:

  • Bacillus anthracis lethal factor (LF) is a key virulence determinant causing severe host pathology.
  • Inhibiting LF protease activity offers a potential therapeutic strategy against anthrax.

Purpose of the Study:

  • To determine the crystal structure of LF complexed with a hydroxamate inhibitor.
  • To evaluate the therapeutic potential of this hydroxamate inhibitor against LF-mediated toxicity.

Main Methods:

  • X-ray crystallography to elucidate the inhibitor-LF complex structure.
  • In vitro enzyme inhibition assays.
  • Cell-based assays using macrophages.
  • In vivo studies in mouse and rabbit anthrax models.

Related Experiment Videos

Main Results:

  • The crystal structure revealed intimate binding of the hydroxamate to the LF active site.
  • The inhibitor demonstrated potent inhibition of LF protease activity and protected cells.
  • Significant protection and increased survival were observed in lethal mouse and rabbit anthrax models.
  • Combination therapy with ciprofloxacin enhanced protection against B. anthracis spore challenge.

Conclusions:

  • Small molecule hydroxamate LF inhibitors can effectively ameliorate anthrax toxemia.
  • This inhibitor represents a promising therapeutic adjunct for anthrax treatment, especially in combination with antibiotics.